Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 4Myelodysplastic Syndromes 2Leukemia, Monocytic, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Leukemia 1

Interventions

ofatumumab 3Vincristine 2Rituximab 2Lenalidomide 2Bortezomib 2tenofovir alafenamide 1pomalidomide 1pivalyloxymethyl butyrate 1pegaspargase 1nelarabine 1immunotoxin HA22 1fludarabine 1bempegaldesleukin 1Whole-Body Irradiation 1Tablets 1Panobinostat 1Observation 1Nivolumab 1Mitoxantrone 1Methotrexate 1Mercaptopurine 1Everolimus 1Etoposide 1Drug Therapy 1Dexamethasone 1DTRMWXHS-12 1Cytarabine 1Cyclophosphamide 1Clofarabine 1Cladribine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia, B-Cell × Cladribine × Clear all
NCT01446900 2018-01-31

R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma

European Institute of Oncology

Phase 2 Terminated
25 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡